[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chittagong Medical College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":195},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,68,90,112,147,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641611","phase-4-comparison-of-propranolol-flunarizine-and-their-combination-in-preventing-migraine-in-adults-in-a-tertiary-care-hospital-in-bangladesh-100641611",false,"NCT07655700","Comparison of Propranolol, Flunarizine and Their Combination in Preventing Migraine in Adults in a Tertiary Care Hospital in Bangladesh","Comparative Efficacy of Propranolol, Flunarizine, and Their Combination in Migraine Prophylaxis: An Open-label Parallel-arm Randomized Controlled Trial","Inclusion Criteria:\n\n1. Participants aged 18 to 55 years.\n2. Diagnosis of episodic migraine, defined according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria.\n3. Participants experiencing 4 or more migraine attacks per month.\n4. Willingness to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Comorbidities:\n\n   * Presence of other primary headache disorders, chronic migraine, hemiplegic migraine, basilar migraine or any secondary headache disorder.\n   * Known serious underlying systemic diseases including Cardiac disease (Heart failure, Heart Block, Arrhythmia), Renal dysfunction, Liver dysfunction, Pulmonary disease (Asthma, COPD), Peripheral vascular disease, Extrapyramidal disease (Parkinson disease, Chorea, Dystonia).\n   * Pregnancy or breastfeeding.\n   * Psychiatric illness (Depression, Psychosis, Obsessive compulsive disorder).\n2. Medications:\n\n   * Received migraine prophylactic medication within 60 days prior to screening.\n   * Use of specific contraindicated medications, including beta-blockers or calcium channel blockers, except as part of the study treatments.\n3. Non-compliance:\n\n   * Inability or unwillingness to comply with study protocols, including maintaining a headache diary or attending follow-up visits.\n4. History of Allergies:\n\n   * Known hypersensitivity to propranolol, flunarizine\n5. Substance Use:\n\n   * Current substance abuse","ALL","18 Years","55 Years",{"count":20,"type":21},177,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Migraine is a common and disabling neurological condition that affects quality of life, work productivity, and daily functioning. In Bangladesh, migraine is a major health problem, yet access to effective and affordable preventive treatments remains limited. Preventive (prophylactic) treatment is recommended for people who experience frequent migraine attacks in order to reduce the number, severity, and duration of headaches.\n\nPropranolol and flunarizine are two commonly used and relatively inexpensive medications for migraine prevention. Both drugs have been shown to reduce migraine frequency when used alone. However, some patients do not respond adequately to a single medication. Using a combination of drugs that work through different mechanisms may improve treatment effectiveness without significantly increasing side effects. There is limited local evidence comparing propranolol, flunarizine, and their combination in migraine prevention, particularly in the Bangladeshi population.\n\nThis study is designed to compare the effectiveness and safety of propranolol alone, flunarizine alone, and a combination of propranolol and flunarizine in preventing episodic migraine in adults. The main hypothesis is that at least one of these treatment strategies, particularly combination therapy, may be more effective than the others in reducing migraine burden.\n\nThis is an open-label, parallel-arm, randomized controlled trial conducted at Chittagong Medical College Hospital, Bangladesh. A total of 177 adult patients aged 18 to 55 years who are diagnosed with episodic migraine and experience four or more migraine attacks per month will be enrolled. Participants will be randomly assigned to one of three treatment groups: propranolol, flunarizine, or a combination of both medications. Treatment will be given for 12 weeks, with dose adjustments during the first week and follow-up visits at 6 and 12 weeks.\n\nThe primary outcome of the study is the reduction in the number of monthly migraine days. Secondary outcomes include the proportion of patients achieving at least a 50% reduction in migraine days, changes in headache severity and duration, improvement in migraine-related disability (measured by the Migraine Disability Assessment Score), patient-reported treatment satisfaction, and the frequency of side effects.\n\nThe results of this study are expected to provide important local evidence to guide clinicians in selecting effective and affordable migraine preventive treatments and to clarify whether combination therapy offers additional benefits over single-drug therapy in routine clinical practice.",[27],"Migraine Prophylaxis",[27,29,30,31,32],"Randomized Controlled Trial","Combination Therapy","Propranolol","Flunarizine","NOT_YET_RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2027-04-30",{"name":43,"class":44},"Chittagong Medical College","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100643575","comparative-effects-of-doxercalciferol-and-calcitriol-on-secondary-hyperparathyroidism-in-esrd-100643575","NCT07640347","Comparative Effects of Doxercalciferol and Calcitriol on Secondary Hyperparathyroidism in ESRD","Effects of Doxercalciferol Compared to Calcitriol for Lowering PTH Level in Hemoodialysis Patients","Inclusion Criteria:\n\n1. Adult patients aged 18 years or older.\n2. Diagnosed with secondary hyperparathyroidism (SHPT) with elevated serum PTH levels (\\>300 pg\u002FmL).\n3. Undergoing maintenance hemodialysis for at least 3 months.\n4. Patients on calcitriol therapy within wash out period 40 hrs.\n\nExclusion Criteria:\n\n1. Patients with known case of primary hyperparathyroidism or parathyroidectomy.\n2. Serum calcium\\>10mg\u002FdL or phosphate\\>5.5mg\u002FdL at baseline.\n3. Active liver disease or significant hepatic dysfunction, Alcoholism.\n4. History of hypersensitivity to vitamin D analogs.\n5. Pregnant or breastfeeding women.\n6. Concurrent use of medications (e.g. bisphosphonates).\n7. Patients with active malignancy.(e.g.Multiple myeloma,Bronchogenic carcinoma)",{"count":54,"type":21},98,[56],"NA","Secondary hyperparathyroidism (SHPT) is a common complication of advanced chronic kidney disease (CKD), caused by phosphate retention and vitamin D deficiency, leading to elevated parathyroid hormone (PTH) levels and increased bone and cardiovascular complications. Active vitamin D analogs such as calcitriol and doxercalciferol are used to suppress PTH levels, though they differ in pharmacologic properties and effects on mineral metabolism. Intravenous preparations may offer improved bioavailability and adherence in hemodialysis patients.This randomized controlled trial will be conducted in the Department of Nephrology at Chittagong Medical College Hospital among 98 adult hemodialysis patients with SHPT. Participants will be randomly assigned to receive either intravenous doxercalciferol or oral calcitriol. The study aims to compare their effectiveness in lowering PTH levels and evaluate safety outcomes.\n\nContinuous variables will be expressed as mean ± standard deviation, while categorical variables will be presented as frequencies and percentages. Independent t-tests, chi-square tests, or Fisher's exact tests will be used for statistical comparisons. Data analysis will be performed using SPSS version 27.0, with a p-value \\\u003C0.05 considered statistically significant.",[59],"Lowering Parathyroid Hormone Level in Patients on Hemodioalysis","2026-06-08",{"date":62,"type":37},"2026-06-10",{"date":64,"type":21},"2026-07-05",{"date":66,"type":21},"2027-05-30",{"name":43,"class":44},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":45},"100639573","phase-3-dapagliflozin-vs-dapagliflozin-finerenone-for-albuminuria-in-ckd-with-type-2-diabetes-100639573","NCT07598864","\"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes\"","Effect of Dapagliflozin Compared to Dapagliflozin-finerenone Combination on Albuminuria in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Randomized Controlled Trial.","Inclusion criteria:\n\nPatients aged ≥ 18 years Patients with T2 DM , as defined by the American Diabetic Association. Urinary ACR ≥ 30 mg\u002Fg and eGFR ≥ 25 ml\u002Fmin per 1.73 m2 Prior treatment with ACEIs or ARBs for more than four weeks up to the maximum tolerated dose Serum potassium ≤ 4.8 mmol\u002FL\n\nExclusion criteria\n\n* Patients with other known causes of proteinuria, e.g. UTI, fever\n* At screening visit SBP higher than 160 mmHg or DBP higher than 100 mmHg or SBP lower than 90 mmHg\n* Glycated hemoglobin (HbA1C) \\>11%\n* Known hypersensitivity to dapagliflozin or finerenone\n* Known case of Addison's disease\n* Known case of hepatic insufficiency\n* Treatment with SGLT2i (empagliflozin:62 hours, dapagliflozin:65hours) or MRAs (finerenone:10-20 hours, spironolactone:7 hours , eplerenone:15-30 hours) within their wash out periods.\n* Patients on non-dihydropyridine Calcium Chanel blockers or Glucagon-like peptide-1 (GLP-1) agonists\n* Pregnant lady or lactating mother",{"count":76,"type":21},88,[78],"PHASE3","Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) is a major cause of morbidity, commonly associated with persistent albuminuria and progressive renal decline. Reducing albuminuria is a key therapeutic goal to slow disease progression. Sodium-glucose cotransporter-2 inhibitors like dapagliflozin and non-steroidal mineralocorticoid receptor antagonists such as finerenone have independently shown significant renoprotective effects. Their combined use may provide additive benefits.\n\nThis open-label randomized controlled trial will be conducted in the Department of Nephrology, Chittagong Medical College Hospital, Bangladesh, including 88 patients with CKD and T2DM. Participants will be randomized into two groups: one receiving dapagliflozin 10 mg plus finerenone 10 mg daily, and the other receiving dapagliflozin 10 mg alone for eight weeks.\n\nThe primary outcome will be the change in urinary albumin-to-creatinine ratio (UACR). Secondary outcomes include serum creatinine, estimated glomerular filtration rate (eGFR), and serum potassium. Safety and adverse events will also be monitored. Data will be analyzed using SPSS version 27.\n\nThis study aims to assess whether combination therapy is more effective than dapagliflozin alone in reducing albuminuria and may help guide treatment strategies in diabetic CKD.",[81],"Diabetic Nephropathy","2026-05-14",{"date":84,"type":37},"2026-05-20",{"date":86,"type":21},"2026-05-01",{"date":88,"type":21},"2027-05-01",{"name":43,"class":44},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100633410","difelikefalin-for-itching-in-hemodialysis-patients-with-chronic-kidney-disease-100633410","NCT07526324","Difelikefalin for Itching in Hemodialysis Patients With Chronic Kidney Disease","Effect of Difelikefalin on CKD-Associated Pruritus in Patients on Maintenance Hemodialysis: A Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged ≥18 years\n* Diagnosed with chronic kidney disease (CKD) on maintenance hemodialysis Undergoing hemodialysis for at least 3 months\n* Presence of moderate-to-severe pruritus defined as Worst Itching Intensity Numerical Rating Scale (WI-NRS) score ≥4\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Known case of Primary skin disesease associated with Itching.\n* Known case of liver disease.\n* Known case of iron defeciency anaemia ,hematological malignancy.\n* Known case of hypothyroidism \\& hyperthyroidism.\n* Known case of allergic reaction to Opiates .\n* Pregnancy.\n* Drug abuse, or substance dependence",{"count":98,"type":21},106,[56],"A randomized, placebo-controlled, double-blind trial will be conducted in the Department of Nephrology at Chittagong Medical College Hospital, Chattogram, Bangladesh, over a period of one and a half years. A total of 102 patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis will be enrolled in the study.\n\nPatients with moderate-to-severe pruritus, defined as a Worst Itching Intensity Numerical Rating Scale (WI-NRS) score ≥ 4, will be included. Eligible participants will be randomly assigned in a 1:1 ratio to receive either difelikefalin (0.5 mcg\u002Fkg) or placebo administered intravenously after each hemodialysis session for 6 weeks.\n\nThe primary outcome measure will be the change in WI-NRS score from baseline to week 6. Secondary outcomes will include changes in quality of life assessed using the Skindex-10 scale. Adverse events and safety parameters will also be monitored throughout the study period.\n\nThe primary analysis will be conducted using the intention-to-treat principle. A per-protocol analysis may also be performed as a secondary analysis. Statistical analysis will be carried out using SPSS version 27.",[102,103],"Itching Symptoms","CKD 5D, Hemodialysis","2026-04-10",{"date":106,"type":37},"2026-04-13",{"date":108,"type":21},"2026-04-26",{"date":110,"type":21},"2027-01-30",{"name":43,"class":44},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100613141","phase-2-levosimendan-in-acute-decompensated-heart-failure-100613141","NCT07262723","Levosimendan in Acute Decompensated Heart Failure","Efficacy and Safety of Levosimendan in Patients With Acute Decompensated Heart Failure: A Real-World Evidence","Inclusion Criteria:\n\n* Adult patients (age \\>18 years)\n* Both male and female sex\n* Having left ventricular dysfunction, evidenced by a left ventricular ejection fraction \\\u003C40% within the prior 12 months\n* Hospitalized for the treatment of ADHF\n* Remained dyspneic at rest despite treatment with intravenous diuretics (NYHA class IV)\n* Patients might have received intravenous vasodilators and\u002For positive inotropic drugs (except amrinone and milrinone), but the infusion rates of these drugs must have remained constant for at least 2 h before entry into the study.\n\nExclusion Criteria:\n\n* History of invasive cardiac procedure\n\n  * Cardiac surgery during lifetime within 3 months prior to screening\n  * Cardiac revascularization within 3 months prior to screening\n  * Left ventricular assist device (LVAD) implantation within 3 months prior to screening\n  * A cardioversion within 4 h prior to screening, or\n  * Cardiac re-synchronization procedure within 30 days prior to screening)\n* Rhythm disorders (e.g. earlier Torsades de Pointes, increased heart rate)\n* Severe ventricular outflow obstruction\n* Angina within 6 h prior to screening\n* Hypotension (a systolic blood pressure \\\u003C90 mmHg) \\[Can be included after resuscitation, when SBP will be \\>90 mmHg by noradrenaline infusion\\]\n* Uncorrected hypokalemia\n* CNS disease (e.g. stroke, TIA)\n* Respiratory (e.g. COPD exacerbation requiring systematic steroids or intubation)\n* Renal insufficiency (e.g. increased serum creatinine clearance rate \\\u003C15 mL\u002Fmin)\n* Hepatic impairment (e.g. significant increase in liver enzymes, \\>5x the upper limit of normal)\n* Decompensation from active infection eg, sepsis\n* Acute bleeding\n* Patient required blood transfusion or Severe anemia (hemoglobin \\\u003C8 g\u002Fl)\n* Serum potassium concentration \\\u003C3.5 or \\>5.4 mmol\u002Fl\n* Use of amrinone and milrinone prior to screening\n* A history of hypersensitivity to levosimendan or any of the excipients\n* Intubated or otherwise unable to communicate\n* Pregnancy\n* Post partum cardiomyopathy\n* Previous participation in a clinical trial with any experimental treatment within the last 30 days",{"count":120,"type":21},332,[122,78],"PHASE2","Acute decompensated heart failure (ADHF) is one of the major causes of hospitalization and mortality worldwide. Despite advances in medical treatments, managing ADHF remains complex, especially in high-risk populations. Levosimendan, a calcium sensitizer that improves myocardial contractility and reduces complications associated with acute decompensated heart failure, has shown potential in improving outcomes in these patients. The present study aims to evaluate the efficacy and safety of levosimendan in patients with ADHF in a real-world clinical setting.\n\nThis pragmatic, multicenter, randomized, controlled trial will include adult patients diagnosed with ADHF in two groups: one receiving levosimendan infusion, and the other receiving standard care for heart failure management, according to the most up-to-date clinical protocols. The study is designed to assess both the efficacy and safety of levosimendan, comparing it with the current standard of care.\n\nThe primary endpoint of the study will be a clinical composite outcome measured from the NYHA functional classification of heart failure and patient global assessment. Secondary endpoints will include change in serum pro-BNP levels, clinical outcome of heart failure, changes in dyspnea status, all-cause and cardiac mortality. Safety endpoints, including adverse events, will also be systematically recorded and analyzed. Adverse events will be closely monitored, categorized as either mild, moderate, or severe, and their potential association with the treatment will be assessed.\n\nData collection will occur at baseline and during subsequent follow-up visits at 6 hours, 24 hours, 5 days (or day of discharge), and 90 days post-treatment. Key efficacy measures will be obtained through clinical evaluations and laboratory tests, including blood pressure, electrocardiogram (ECG) findings, and NT-proBNP serum levels. The statistical analysis will follow an intention-to-treat (ITT) and Per protocol (PP) approach to account for all enrolled patients, ensuring robust and generalizable findings. This study will be conducted in accordance with Good Clinical Practice (GCP) guidelines and ethical standards outlined in the Declaration of Helsinki, prioritizing participant safety and scientific rigor throughout the study.\n\n12 The results of this trial will provide critical insights into the potential benefits of levosimendan for treating ADHF, and could potentially inform clinical decision-making, offering a more effective therapeutic option in managing this life-threatening condition.",[125],"Acute Decompensated Heart Failure (ADHF)",[127,128,129,130,131,132,133,134,135,136,137],"Acute decompensated heart failure (ADHF)","Levosimendan","Real-world evidence","Efficacy","Safety","NT-proBNP \u002F pro-BNP levels","Randomized controlled trial (RCT)","Electrocardiogram (ECG)","Good Clinical Practice (GCP)","Declaration of Helsinki","Adverse events","2025-11-23",{"date":140,"type":37},"2025-12-04",{"date":142,"type":21},"2025-12-01",{"date":144,"type":21},"2026-12-30",{"name":43,"class":44},6,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":45},"100581194","effect-of-zinc-supplementation-on-hyperhomocysteinemia-compared-to-folic-acid-in-ckd-patient-on-hemodialysis-100581194","NCT06847139","Effect of Zinc Supplementation on Hyperhomocysteinemia Compared to Folic Acid in CKD Patient on Hemodialysis","Effect of Zinc Supplementation on Hyperhomocysteinemia Compared to That of Folic Acid in Patients of Chronic Kidney Disease on Hemodialysis-A Randomized Controlled Trial.","CKD","Inclusion Criteria:\n\n* 1\\. Age ≥18 years 2. Patient with chronic kidney disease on HD for ≥ 3 months 3. Plasma homocysteine level \\> 15μmol\u002FL\n\nExclusion Criteria:\n\n1. Acute illness at the time of inclusion.\n2. Diagnosed case of malabsorption\n3. Planned major surgery\n4. Renal transplantation\n5. Receiving zinc or folic acid supplementation within the previous month from enrollment.\n6. Concomitant use of vitamin B 12 supplementation(6 days), corticosteroid (18-36 hour), anti folate or cytotoxic drugs, quinolones, tetracyclines, bisphosphonates.\n7. Known hypersensitivity to zinc or folic acid.\n\n   \\-",{"count":156,"type":21},90,[56],"Hyperhomocysteinemia is a well-recognized risk factor for accelerated cardiovascular events in hemodialysis patients. Hyperhomocysteinemia is common in individuals with chronic kidney disease (CKD). Zinc is a vital cofactor for homocysteine metabolism enzymes. Although numerous studies have demonstrated the efficacy of folic acid in hyperhomocysteinemia, zinc supplementation has the potential to reduce homocysteine levels in hemodialysis patients. Objective: To evaluate the effect of Zinc supplementation on hyperhomocysteinemia compared to that of folic acid in patients with chronic kidney disease on hemodialysis. Materials and Methods: This open-label randomized active-controlled trial will be conducted in the Department of Nephrology of Chittagong Medical College Hospital, Chattogram, Bangladesh, for one and a half years. A total of ninety CKD patients on maintenance hemodialysis will be included in the study. Patients will be randomly divided into two groups. The experimental group will be treated with zinc sulfate (50 mg elemental zinc\u002Fday) for six weeks in conjunction with conventional treatment for CKD. The Control group will receive folic acid (5mg\u002Fday) along with conventional medications for CKD. The primary outcome measure will be the change in the plasma homocysteine level after 6 weeks, while the other variables will include serum creatinine, eGFR, serum albumin and C-reactive protein (CRP) level. Adverse events and safety measures will also be recorded. The primary analysis will be an intention to treat analysis performed with SPSS-23. Data from previous studies indicate zinc supplementation can reduce homocysteine levels in CKD patients facilitating its metabolism. Additionally, the anti-inflammatory properties of zinc may facilitate homocysteine reduction. Moreover, zinc is crucial in various physiological processes, including immune function, protein synthesis, and wound healing. Further clinical trials are still needed to understand better the safety and efficacy of zinc supplementation in CKD patients.",[160],"Chronic Kidney Disease Requiring Hemodialysis","RECRUITING","2025-05-22",{"date":164,"type":37},"2025-05-23",{"date":166,"type":37},"2024-07-01",{"date":168,"type":21},"2025-10-30",{"name":43,"class":44},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":177,"sex":16,"minAge":17,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":45},"100554684","evaluation-of-antibiotic-administration-following-tooth-extraction-100554684","NCT06502288","Evaluation of Antibiotic Administration Following Tooth Extraction","Evaluation of Necessity of Antibiotic Administration Following Tooth Extraction: A Randomized Control Trial","Inclusion Criteria:\n\n1. Patient indicated extraction of teeth\n2. Provide informed written consent\n3. Patients aged between 18 to 50 years\n\nExclusion Criteria:\n\n1. The tooth with abscess, infected cyst and tumors that require extensive surgery including impacted teeth\n2. Patients who have taken antibiotics before 5 days for any reason will be excluded\n3. Patients who are medically compromised such as DM, Congenital cyanotic heart disease, chronic kidney disease (CKD), Patients with chemotherapy or radiotherapy, Chronic Liver Disease (CLD), etc.\n4. Female patients who are pregnant or lactating\n5. Those women during the menstruation period (disturbed fibrinolytic activity),\n6. Participants who are known hypersensitive to the given drugs used in this study\n7. Participants who have known resistance to intervention drugs",true,"50 Years",{"count":180,"type":21},152,[56],"The trial aims to evaluate the effects of prescribing antibiotics after tooth extraction. 152 dental patients aged 18 to 50 will be randomly assigned. The study will assess infection rates, healing times, pain, and adverse effects in patients who receive antibiotics versus those who do not. The trial will be conducted at the Oral and Maxillofacial Surgery Department, Dental Unit, Chittagong Medical College. Data analysis will involve the use of the χ²-test, t-tests, and logistic regression, with a significance level of 5%. Ethical considerations include obtaining informed consent from all participants, and safety will be monitored by an independent expert team.",[184],"Tooth Extraction",[186],"Antibiotic, tooth extraction, RCT","2024-07-13",{"date":189,"type":37},"2024-07-16",{"date":191,"type":21},"2025-01-01",{"date":193,"type":21},"2025-10-15",{"name":43,"class":44},""]